Hu Q, Tian H, Wu Q, Li J, Cheng X, Liao P
Chongqing Center for Clinical Laboratory, Yuzhong, Chongqing, China; Department of Clinical Laboratory Medicine, Third People's Hospital of Chongqing, Yuzhong, Chongqing, China.
Department of Cardiology, Banan People's Hospital of Chongqing, Banan, Chongqing, China.
Transplant Proc. 2015 Jul-Aug;47(6):1746-53. doi: 10.1016/j.transproceed.2015.04.090.
Interleukin-2 (IL-2) -330 T/G promoter polymorphism is involved in the acute rejection (AR) risk of kidney transplantation. However, results from published studies on the association between recipient IL-2-330 T/G polymorphism and AR risk are conflicting and inconclusive.
We searched Medline, Embase, Web of Science, and Cochrane Central Register from their inceptions through January 2015 for relevant studies. Data concerning publication information, population characteristics, and transplant information were extracted. Odds ratios (ORs) were calculated for the association between IL-2-330 T/G polymorphism and AR risk.
This meta-analysis included 8 case-control studies with 1,405 cases of renal transplant recipients. The pooled estimate showed that IL-2-330 T/G polymorphism was not associated with AR risk: TT vs TG+GG: OR(fixed,) 0.93; 95% confidence interval [CI], 0.72-1.21; P = .60; GG vs TG+TT: OR(fixed), 1.15; 95% CI, 0.76-1.72; P = .51; TG vs TT+GG: OR(fixed), 1.01; 95% CI, 0.78-1.31; P = .91; T vs G: OR(fixed), 0.93; 95% CI, 0.77-1.13; P = .48. None of subgroup analyses yielded significant results in the association between IL-2-330 T/G polymorphism and AR risk. Meta-regression confirmed that there was no significant correlation between the preselected trial characteristics and our study results.
This meta-analysis suggests that IL-2-330 T/G polymorphism may not be associated with AR risk in renal transplant recipients.
白细胞介素-2（IL-2）-330 T/G启动子多态性与肾移植急性排斥反应（AR）风险相关。然而，已发表的关于受者IL-2-330 T/G多态性与AR风险关联的研究结果相互矛盾且尚无定论。
我们检索了Medline、Embase、科学引文索引和考克兰中央对照试验注册库，从建库至2015年1月的相关研究。提取有关发表信息、人群特征和移植信息的数据。计算IL-2-330 T/G多态性与AR风险关联的比值比（OR）。
这项荟萃分析纳入了8项病例对照研究，共1405例肾移植受者。汇总估计显示，IL-2-330 T/G多态性与AR风险无关：TT与TG+GG比较：OR（固定效应），0.93；95%置信区间[CI]，0.72 - 1.21；P = 0.60；GG与TG+TT比较：OR（固定效应），1.15；95% CI，0.76 - 1.72；P = 0.51；TG与TT+GG比较：OR（固定效应），1.01；95% CI，0.78 - 1.31；P = 0.91；T与G比较：OR（固定效应），0.93；95% CI，0.77 - 1.13；P = 0.48。亚组分析均未得出IL-2-330 T/G多态性与AR风险关联的显著结果。Meta回归证实，预先选定的试验特征与我们的研究结果之间无显著相关性。
这项荟萃分析表明，IL-2-330 T/G多态性可能与肾移植受者的AR风险无关。
